
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4022414/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	SARS-CoV-2-Specific Antibody (Ab) Levels and the Kinetic of Ab Decline Determine Ab Persistence Over 1 Year. Frontiers in Medicine, 2022, 9, 822316.	1.2	2
2	Monitoring of heat- and light exposure of cell culture media by RAMAN spectroscopy: Towards an analytical tool for cell culture media quality control. Biochemical Engineering Journal, 2021, 166, 107845.	1.8	7
3	Directed Evolution of Stabilized Monomeric CD19 for Monovalent CAR Interaction Studies and Monitoring of CAR-T Cell Patients. ACS Synthetic Biology, 2021, 10, 1184-1198.	1.9	9
4	Shake tube perfusion cell cultures are suitable tools for the prediction of limiting substrate, <scp>CSPR</scp> , bleeding strategy, growth and productivity behavior. Journal of Chemical Technology and Biotechnology, 2021, 96, 2930-2939.	1.6	11
5	Eukaryotic Expression Systems for Upstream Processing of Monoclonal Antibodies. Learning Materials in Biosciences, 2021, , 343-362.	0.2	Ο
6	Functional Trimeric SARS-CoV-2 Envelope Protein Expressed in Stable CHO Cells. Frontiers in Bioengineering and Biotechnology, 2021, 9, 779359.	2.0	4
7	Rapid development of cloneâ€specific, highâ€performing perfusion media from established feed supplements. Biotechnology Progress, 2020, 36, e2933.	1.3	13
8	Transient pentameric IgM fulfill biological function—Effect of expression host and transfection on IgM properties. PLoS ONE, 2020, 15, e0229992.	1.1	4
9	Getting CD19 Into Shape: Expression of Natively Folded "Difficult-to- Express―CD19 for Staining and Stimulation of CAR-T Cells. Frontiers in Bioengineering and Biotechnology, 2020, 8, 49.	2.0	9
10	Inefficient CAR-proximal signaling blunts antigen sensitivity. Nature Immunology, 2020, 21, 848-856.	7.0	83
11	Screening of Media Supplements for High-Performance Perfusion Cultures by Design of Experiment. Methods in Molecular Biology, 2020, 2095, 27-39.	0.4	3
12	Analysis of Product Quality of Complex Polymeric IgM Produced by CHO Cells. Methods in Molecular Biology, 2020, 2095, 295-302.	0.4	0
13	Germinality does not necessarily define mAb expression and thermal stability. Applied Microbiology and Biotechnology, 2019, 103, 7505-7518.	1.7	3
14	Impact of temperature and pH on recombinant human IgM quality attributes and productivity. New Biotechnology, 2019, 50, 20-26.	2.4	12
15	Comparative Antigenicity of Thiourea and Adipic Amide Linked Neoglycoconjugates Containing Modified Oligomannose Epitopes for the Carbohydrate-Specific anti-HIV Antibody 2G12. Bioconjugate Chemistry, 2019, 30, 70-82.	1.8	15
16	Bioprocessing of Recombinant CHO-K1, CHO-DG44, and CHO-S: CHO Expression Hosts Favor Either mAb Production or Biomass Synthesis. Biotechnology Journal, 2019, 14, 1700686.	1.8	44
17	Multiple reaction monitoring targeted LC-MS analysis of potential cell death marker proteins for increased bioprocess control. Analytical and Bioanalytical Chemistry, 2018, 410, 3197-3207.	1.9	7
18	Differential gene expression of a feed-spiked super-producing CHO cell line. Journal of Biotechnology, 2018, 285, 23-37.	1.9	14

#	Article	IF	CITATIONS
19	Lessons learned from merging wet lab experiments with molecular simulation to improve mAb humanization. Protein Engineering, Design and Selection, 2018, 31, 257-265.	1.0	6
20	Nomenclature of humanized mAbs: Early concepts, current challenges and future perspectives. Human Antibodies, 2018, 27, 37-51.	0.6	27
21	Cloning of Single-Chain Antibody Variants by Overlap-Extension PCR for Evaluation of Antibody Expression in Transient Gene Expression. Methods in Molecular Biology, 2017, 1603, 57-69.	0.4	1
22	Glycan profile of CHO derived IgM purified by highly efficient single step affinity chromatography. Analytical Biochemistry, 2017, 539, 162-166.	1.1	16
23	A human monocytic NF-κB fluorescent reporter cell line for detection of microbial contaminants in biological samples. PLoS ONE, 2017, 12, e0178220.	1.1	28
24	Proteomic differences in recombinant CHO cells producing two similar antibody fragments. Biotechnology and Bioengineering, 2016, 113, 1902-1912.	1.7	29
25	Biphasic cultivation strategy to avoid Epo-Fc aggregation and optimize protein expression. Journal of Biotechnology, 2016, 227, 3-9.	1.9	18
26	Antibody humanization by molecular dynamics simulations— <i>inâ€silico</i> guided selection of critical backmutations. Journal of Molecular Recognition, 2016, 29, 266-275.	1.1	29
27	Advances in recombinant antibody manufacturing. Applied Microbiology and Biotechnology, 2016, 100, 3451-3461.	1.7	291
28	Identification of bottlenecks in antibody expression using targeted gene integration. BMC Proceedings, 2015, 9, P7.	1.8	1
29	Improved Protocol for Rapid Identification of Certain Spa Types Using High Resolution Melting Curve Analysis. PLoS ONE, 2015, 10, e0116713.	1.1	14
30	Upstream and downstream processing of recombinant IgA. Biotechnology Letters, 2015, 37, 241-251.	1.1	13
31	Introduction of germline residues improves the stability of anti-HIV mAb 2G12-IgM. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2015, 1854, 1536-1544.	1.1	7
32	Benchmarking of commercially available CHO cell culture media for antibody production. Applied Microbiology and Biotechnology, 2015, 99, 4645-4657.	1.7	105
33	Heterologous protein production using euchromatin-containing expression vectors in mammalian cells. Nucleic Acids Research, 2015, 43, e102-e102.	6.5	46
34	Evaluating the bottlenecks of recombinant IgM production in mammalian cells. Cytotechnology, 2015, 67, 343-356.	0.7	23
35	Novel Bifunctional Single-Chain Variable Antibody Fragments to Enhance Virolysis by Complement: Generation and Proof-of-Concept. BioMed Research International, 2014, 2014, 1-14.	0.9	2
36	Generation of a Canine Anti-EGFR (ErbB-1) Antibody for Passive Immunotherapy in Dog Cancer Patients. Molecular Cancer Therapeutics, 2014, 13, 1777-1790.	1.9	45

#	Article	IF	CITATIONS
37	Stable overexpression of miR-17 enhances recombinant protein production of CHO cells. Journal of Biotechnology, 2014, 175, 38-44.	1.9	67
38	In search of expression bottlenecks in recombinant CHO cell lines—a case study. Applied Microbiology and Biotechnology, 2014, 98, 5959-5965.	1.7	21
39	Novel human renal proximal tubular cell line for the production of complex proteins. Journal of Biotechnology, 2014, 176, 29-39.	1.9	6
40	Accurate comparison of antibody expression levels by reproducible transgene targeting in engineered recombination-competent CHO cells. Applied Microbiology and Biotechnology, 2014, 98, 9723-9733.	1.7	14
41	Establishment of stable, high producing, recombinant CHO cell lines using Rosa26 Bacterial Artificial Chromosomes for transgene delivery. New Biotechnology, 2014, 31, S187.	2.4	0
42	Advanced clarification of cell culture supernatant by 3Mâ,,¢ Emphazeâ,,¢ AEX Hybrid Purifier for fast and economic bioprocessing of recombinant proteins. New Biotechnology, 2014, 31, S117-S118.	2.4	0
43	RMCE reference sites – A valuable tool for comparing antibody expression capabilities in CHO cells. New Biotechnology, 2014, 31, S186-S187.	2.4	0
44	Cross-species comparison of recombinant protein secretion in CHO cells and Pichia pastoris. New Biotechnology, 2014, 31, S4.	2.4	0
45	Identification of microRNAs specific for high producer CHO cell lines using steady-state cultivation. Applied Microbiology and Biotechnology, 2014, 98, 7535-7548.	1.7	29
46	<i>Pichia pastoris</i> secretes recombinant proteins less efficiently than Chinese hamster ovary cells but allows higher spaceâ€ŧime yields for less complex proteins. Biotechnology Journal, 2014, 9, 526-537.	1.8	55
47	Transgene copy number comparison in recombinant mammalian cell lines: critical reflection of quantitative real-time PCR evaluation. Cytotechnology, 2013, 65, 811-818.	0.7	11
48	Characterization of recombinant IgA producing CHO cell lines by qPCR. BMC Proceedings, 2013, 7, P114.	1.8	4
49	Powerful expression in Chinese Hamster Ovary cells using bacterial artificial chromosomes: parameters influencing productivity. BMC Proceedings, 2013, 7, .	1.8	7
50	Exploration of BAC versus plasmid expression vectors in recombinant CHO cells. Applied Microbiology and Biotechnology, 2013, 97, 4049-4054.	1.7	22
51	Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients. MAbs, 2013, 5, 801-809.	2.6	66
52	Recent advances in recombinant protein production. Bioengineered, 2013, 4, 258-261.	1.4	20
53	Recombinant IgM expression in mammalian cells: A target protein challenging biotechnological production. Advances in Bioscience and Biotechnology (Print), 2013, 04, 38-43.	0.3	15
54	One-Step Triplex High-Resolution Melting Analysis for Rapid Identification and Simultaneous Subtyping of Frequently Isolated Salmonella Serovars. Applied and Environmental Microbiology, 2012, 78, 3352-3360.	1.4	19

#	Article	IF	CITATIONS
55	The Neutralizing Anti-HIV Antibody 2G12. , 2012, , 147-160.		0
56	Growth, productivity and protein glycosylation in a CHO EpoFc producer cell line adapted to glutamine-free growth. Journal of Biotechnology, 2012, 157, 295-303.	1.9	45
57	Bacterial artificial chromosome versus conventional vector based protein expression in CHO cells: a comparison study. New Biotechnology, 2012, 29, S162.	2.4	0
58	Strategies for Efficient Transfection of CHO-Cells with Plasmid DNA. Methods in Molecular Biology, 2012, 801, 213-226.	0.4	5
59	Evaluation of the Potency of the Anti-Idiotypic Antibody Ab2/3H6 Mimicking gp41 as an HIV-1 Vaccine in a Rabbit Prime/Boost Study. PLoS ONE, 2012, 7, e39063.	1.1	7
60	A screening method to assess biological effects of microRNA overexpression in Chinese hamster ovary cells. Biotechnology and Bioengineering, 2012, 109, 1376-1385.	1.7	45
61	Recombinant Fab expression and secretion in Escherichia coli continuous culture at medium cell densities: Influence of temperature. Process Biochemistry, 2012, 47, 446-452.	1.8	21
62	Recombinant IgA production: Single step affinity purification using camelid ligands and product characterization. Journal of Immunological Methods, 2012, 378, 95-101.	0.6	28
63	Recognition of Membrane-Bound Fusion-Peptide/MPER Complexes by the HIV-1 Neutralizing 2F5 Antibody: Implications for Anti-2F5 Immunogenicity. PLoS ONE, 2012, 7, e52740.	1.1	9
64	Approaches for Humanization of an Anti-idiotypic Murine Monoclonal Antibody. , 2012, , 593-598.		0
65	Production of monoclonal antibodies with a controlled <i>N</i> â€glycosylation pattern in seeds of <i>Arabidopsis thaliana</i> . Plant Biotechnology Journal, 2011, 9, 179-192.	4.1	50
66	3D6 and 4B3: Recombinant expression of two anti-gp41 antibodies as dimeric and secretory IgA. BMC Proceedings, 2011, 5, P56.	1.8	0
67	Anti-idiotypic antibody Ab2/3H6 mimicking gp41: a potential HIV-1 vaccine?. BMC Proceedings, 2011, 5, P64.	1.8	1
68	Influence of growth temperature on the production of antibody Fab fragments in different microbes: A host comparative analysis. Biotechnology Progress, 2011, 27, 38-46.	1.3	46
69	Next-generation sequencing of the Chinese hamster ovary microRNA transcriptome: Identification, annotation and profiling of microRNAs as targets for cellular engineering. Journal of Biotechnology, 2011, 153, 62-75.	1.9	102
70	Expression of Antibody Fragments with a Controlled <i>N</i> -Glycosylation Pattern and Induction of Endoplasmic Reticulum-Derived Vesicles in Seeds of Arabidopsis Â. Plant Physiology, 2011, 155, 2036-2048.	2.3	50
71	Interaction of Anti-HIV Type 1 Antibody 2F5 with Phospholipid Bilayers and Its Relevance for the Mechanism of Virus Neutralization. AIDS Research and Human Retroviruses, 2011, 27, 863-876.	0.5	11
72	Molecular Simulations to Rationalize Humanized Ab2/3H6 Activity. Australian Journal of Chemistry, 2011, 64, 900.	0.5	3

#	Article	IF	CITATIONS
73	Comparison of hybridization methods and real-time PCR: their value in animal cell line characterization. Applied Microbiology and Biotechnology, 2010, 87, 419-425.	1.7	17
74	IgM characterization directly performed in crude culture supernatants by a new simple electrophoretic method. Journal of Immunological Methods, 2010, 359, 21-27.	0.6	15
75	Confocal microscopy of giant vesicles supports the absence of HIVâ€1 neutralizing 2F5 antibody reactivity to plasma membrane phospholipids. FEBS Letters, 2010, 584, 1591-1596.	1.3	19
76	Membrane pore formation by the human immunodeficiency virus type-1 neutralizing anti-gp41 antibody 2F5. Chemistry and Physics of Lipids, 2010, 163, S46.	1.5	0
77	Fc-Glycosylation Influences Fcl ³ Receptor Binding and Cell-Mediated Anti-HIV Activity of Monoclonal Antibody 2G12. Journal of Immunology, 2010, 185, 6876-6882.	0.4	138
78	In Planta Protein Sialylation through Overexpression of the Respective Mammalian Pathway. Journal of Biological Chemistry, 2010, 285, 15923-15930.	1.6	193
79	Inhibition of <i>In Vivo</i> HIV Infection in Humanized Mice by Gene Therapy of Human Hematopoietic Stem Cells with a Lentiviral Vector Encoding a Broadly Neutralizing Anti-HIV Antibody. Journal of Virology, 2010, 84, 6645-6653.	1.5	75
80	Topological transformation of liposomes by a membrane-affecting domain of recombinant human erythropoietin. Journal of Liposome Research, 2010, 20, 24-30.	1.5	1
81	Proline Is Not Uniquely Capable of Providing the Pivot Point for Domain Swapping in 2G12, a Broadly Neutralizing Antibody against HIV-1*. Journal of Biological Chemistry, 2010, 285, 1122-1127.	1.6	12
82	Humanization strategies for an anti-idiotypic antibody mimicking HIV-1 gp41. Protein Engineering, Design and Selection, 2010, 23, 947-954.	1.0	16
83	Characterization of an Anti-Idiotypic Antibody Blocking the Capacity of the HIV-1 Specific nMAb 2F5. , 2010, , 803-806.		0
84	Serum-free transfection of CHO cells with chemically defined transfection systems and investigation of their potential for transient and stable transfection. Cytotechnology, 2009, 60, 115-123.	0.7	18
85	CHO-recombinant human growth hormone as a protease sensitive reporter protein. Applied Microbiology and Biotechnology, 2009, 84, 693-699.	1.7	0
86	A close look at human IgG sialylation and subclass distribution after lectin fractionation. Proteomics, 2009, 9, 4143-4153.	1.3	89
87	A study on the temperature dependency and time course of the cold capture antibody secretion assay. Journal of Biotechnology, 2009, 141, 80-83.	1.9	34
88	Improved Virus Neutralization by Plant-produced Anti-HIV Antibodies with a Homogeneous β1,4-Galactosylated N-Glycan Profile. Journal of Biological Chemistry, 2009, 284, 20479-20485.	1.6	156
89	The absence of effect of gene copy number and mRNA level on the amount of mAb secretion from mammalian cells. Applied Microbiology and Biotechnology, 2008, 81, 701-710.	1.7	25
90	Expression, Purification, and In Vivo Administration of a Promising Anti-Idiotypic HIV-1 Vaccine. Molecular Biotechnology, 2008, 39, 119-125.	1.3	6

#	Article	IF	CITATIONS
91	Analysis of immunoglobulin glycosylation by LCâ€ESIâ€MS of glycopeptides and oligosaccharides. Proteomics, 2008, 8, 2858-2871.	1.3	294
92	Transcriptional profiling of phenotypically different Epoâ€Fc expressing CHO clones by crossâ€species microarray analysis. Biotechnology Journal, 2008, 3, 924-937.	1.8	22
93	Effect of Increased Expression of Protein Disulfide Isomerase and Heavy Chain Binding Protein on Antibody Secretion in a Recombinant CHO Cell Line. Biotechnology Progress, 2008, 21, 106-111.	1.3	164
94	Recombinant antibody 2G12 produced in maize endosperm efficiently neutralizes HIVâ€1 and contains predominantly singleâ€GlcNAc <i>N</i> â€glycans. Plant Biotechnology Journal, 2008, 6, 189-201.	4.1	166
95	Lipid modulation of membraneâ€bound epitope recognition and blocking by HIVâ€1 neutralizing antibodies. FEBS Letters, 2008, 582, 3798-3804.	1.3	19
96	Crystal Structure of the Complex between the Fab′ Fragment of the Cross-Neutralizing Anti-HIV-1 Antibody 2F5 and the Fab Fragment of Its Anti-idiotypic Antibody 3H6. Journal of Molecular Biology, 2008, 382, 910-919.	2.0	20
97	Structural analysis and in vivo administration of an anti-idiotypic antibody against mAb 2F5. Molecular Immunology, 2008, 45, 1027-1034.	1.0	12
98	The Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 4E10 Monoclonal Antibody Is Better Adapted to Membrane-Bound Epitope Recognition and Blocking than 2F5. Journal of Virology, 2008, 82, 8986-8996.	1.5	44
99	A peptide inhibitor of HIVâ€1 neutralizing antibody 2G12 is not a structural mimic of the natural carbohydrate epitope on gp120. FASEB Journal, 2008, 22, 1380-1392.	0.2	31
100	Functional analysis of the broadly neutralizing human antiâ€HIVâ€1 antibody 2F5 produced in transgenic BYâ€2 suspension cultures. FASEB Journal, 2007, 21, 1655-1664.	0.2	84
101	A plant-derived human monoclonal antibody induces an anti-carbohydrate immune response in rabbits. Glycobiology, 2007, 18, 235-241.	1.3	105
102	Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data. Aids, 2007, 21, 2161-2170.	1.0	44
103	Characterisation of recombinant CHO cell lines by investigation of protein productivities and genetic parameters. Journal of Biotechnology, 2007, 128, 716-725.	1.9	45
104	High level expression of a promising anti-idiotypic antibody fragment vaccine against HIV-1 in Pichia pastoris. Journal of Biotechnology, 2007, 128, 735-746.	1.9	41
105	Improvement of the energy metabolism of recombinant CHO cells by cell sorting for reduced mitochondrial membrane potential. Journal of Biotechnology, 2007, 129, 651-657.	1.9	27
106	Partial Humanization and Characterization of an Anti-idiotypic Antibody against Monoclonal Antibody 2F5, a Potential HIV Vaccine?. AIDS Research and Human Retroviruses, 2007, 23, 1405-1415.	0.5	13
107	Protein-free transfection of CHO host cells with an IgG-fusion protein: Selection and characterization of stable high producers and comparison to conventionally transfected clones. Biotechnology and Bioengineering, 2007, 96, 1118-1126.	1.7	34
108	Applicability of different fluorescent dyes for isoform quantification on linear IPG gels. Electrophoresis, 2007, 28, 2100-2107.	1.3	6

#	Article	IF	CITATIONS
109	Production of a monoclonal antibody in plants with a humanized <i>N</i> â€glycosylation pattern. Plant Biotechnology Journal, 2007, 5, 657-663.	4.1	179
110	Serum-free transfection of CHO-cells with tailor-made unilamellar vesicles. Cytotechnology, 2007, 54, 157-168.	0.7	6
111	Validated Method for Quantification of Gentically Modified Organisms in Samples of Maize Flour. Journal of Agricultural and Food Chemistry, 2006, 54, 678-681.	2.4	10
112	Specific phospholipid recognition by human immunodeficiency virus type-1 neutralizing anti-gp41 2F5 antibody. FEBS Letters, 2006, 580, 2395-2399.	1.3	46
113	Biochemical characterization of rhEpo-Fc fusion protein expressed in CHO cells. Protein Expression and Purification, 2006, 49, 265-275.	0.6	53
114	A novel strategy for quantitative isoform detection directly performed from culture supernatant. Journal of Pharmaceutical and Biomedical Analysis, 2006, 42, 322-327.	1.4	7
115	Identification of transgene integration loci of different highly expressing recombinant CHO cell lines by FISH. Cytotechnology, 2006, 51, 171-182.	0.7	23
116	Engineering ofPichia pastoris for improved production of antibody fragments. Biotechnology and Bioengineering, 2006, 94, 353-361.	1.7	177
117	Process parameter shifting: Part II. Biphasic cultivation—A tool for enhancing the volumetric productivity of batch processes using Epo-Fc expressing CHO cells. Biotechnology and Bioengineering, 2006, 94, 1045-1052.	1.7	72
118	Process parameter shifting: Part I. Effect of DOT, pH, and temperature on the performance of Epo-Fc expressing CHO cells cultivated in controlled batch bioreactors. Biotechnology and Bioengineering, 2006, 94, 1033-1044.	1.7	186
119	Recognition and Blocking of HIV-1 gp41 Pre-transmembrane Sequence by Monoclonal 4E10 Antibody in a Raft-like Membrane Environment. Journal of Biological Chemistry, 2006, 281, 39598-39606.	1.6	41
120	Membrane Association and Epitope Recognition by HIV-1 Neutralizing Anti-gp41 2F5 and 4E10 Antibodies. AIDS Research and Human Retroviruses, 2006, 22, 998-1006.	0.5	63
121	HIV-1 mutants escaping neutralization by the human antibodies 2F5, 2G12, and 4E10: in vitro experiments versus clinical studies. Aids, 2005, 19, 1957-1966.	1.0	45
122	Establishment of a strategy for the rapid generation of a monoclonal antibody against the human protein SNEV (hNMP200) by flow-cytometric cell sorting. Journal of Immunological Methods, 2005, 307, 13-23.	0.6	7
123	Cardiolipin Polyspecific Autoreactivity in Two Broadly Neutralizing HIV-1 Antibodies. Science, 2005, 308, 1906-1908.	6.0	704
124	Anti-Human Immunodeficiency Virus Type 1 (HIV-1) Antibodies 2F5 and 4E10 Require Surprisingly Few Crucial Residues in the Membrane-Proximal External Region of Glycoprotein gp41 To Neutralize HIV-1. Journal of Virology, 2005, 79, 1252-1261.	1.5	259
125	Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. Molecular Immunology, 2005, 42, 1311-1319.	1.0	99
126	Broadly Neutralizing Anti-HIV Antibody 4E10 Recognizes a Helical Conformation of a Highly Conserved Fusion-Associated Motif in gp41. Immunity, 2005, 22, 163-173.	6.6	410

#	Article	IF	CITATIONS
127	The Long Third Complementarity-Determining Region of the Heavy Chain Is Important in the Activity of the Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5. Journal of Virology, 2004, 78, 3155-3161.	1.5	111
128	Binding of the 2F5 Monoclonal Antibody to Native and Fusion-Intermediate Forms of Human Immunodeficiency Virus Type 1 gp41: Implications for Fusion-Inducing Conformational Changes. Journal of Virology, 2004, 78, 2627-2631.	1.5	87
129	Screening for improved cell performance: Selection of subclones with altered production kinetics or improved stability by cell sorting. Biotechnology and Bioengineering, 2004, 88, 699-706.	1.7	39
130	Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1 Monoclonal Antibodies. Journal of Virology, 2004, 78, 13232-13252.	1.5	665
131	Characterization of Molecular Features, Antigen-Binding, andin VitroProperties of IgG and IgM Variants of 4E10, an Anti-HIV Type 1 Neutralizing Monoclonal Antibody. AIDS Research and Human Retroviruses, 2004, 20, 755-762.	0.5	74
132	Electron microscopic and immunochemical analysis of the broadly neutralizing HIV-1-specific, anti-carbohydrate antibody, 2G12. Molecular Immunology, 2004, 41, 1001-1011.	1.0	22
133	Inhibition of Human Immunodeficiency Virus Type 1 Entry in Cells Expressing gp41-Derived Peptides. Journal of Virology, 2004, 78, 568-575.	1.5	141
134	Characterization of Human Class-Switched Polymeric (Immunoglobulin M [IgM] and IgA) Anti-Human Immunodeficiency Virus Type 1 Antibodies 2F5 and 2G12. Journal of Virology, 2003, 77, 4095-4103.	1.5	94
135	Antibody Domain Exchange Is an Immunological Solution to Carbohydrate Cluster Recognition. Science, 2003, 300, 2065-2071.	6.0	736
136	Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans. Aids, 2002, 16, 2019-2025.	1.0	86
137	Anti-idiotypic antibody Ab2/3H6 mimics the epitope of the neutralizing anti-HIV-1 monoclonal antibody 2F5. Aids, 2002, 16, 667-668.	1.0	24
138	Analysis of alterations in gene expression after amplification of recombinant genes in CHO cells. Journal of Biotechnology, 2001, 87, 59-65.	1.9	8
139	A Potent Cross-Clade Neutralizing Human Monoclonal Antibody against a Novel Epitope on gp41 of Human Immunodeficiency Virus Type 1. AIDS Research and Human Retroviruses, 2001, 17, 1757-1765.	0.5	470
140	Cross-Neutralizing Human Monoclonal Anti-HIV-1 Antibody 2F5: Preparation and Crystallographic Analysis of the Free and Epitope-Complexed Forms of its F ab Fragment. Protein and Peptide Letters, 2001, 8, 413-418.	0.4	11
141	Stable recombinant expression of the anti HIV-1 monoclonal antibody 2F5 after IgG3/IgG1 subclass switch in CHO cells. Biotechnology and Bioengineering, 2000, 67, 97-103.	1.7	53
142	Optimization of Sorting Conditions for the Selection of Stable, High-Producing Mammalian Cell Lines. Biotechnology Progress, 1999, 15, 953-957.	1.3	36
143	Analysis of changes during subclone development and ageing of human antibody-producing heterohybridoma cells by Northern blot and flow cytometry1This paper was presented at the American Chemical Society Spring National Meeting in San Francisco, April 1997.1. Journal of Biotechnology, 1999. 67. 57-66.	1.9	38
144	Changes during subclone development and ageing of human antibody-producing recombinant CHO cells. Journal of Biotechnology, 1999, 69, 215-226.	1.9	63

#	Article	IF	CITATIONS
145	Molecular Characterization of Five Neutralizing Anti-HIV Type 1 Antibodies: Identification of Nonconventional D Segments in the Human Monoclonal Antibodies 2G12 and 2F5. AIDS Research and Human Retroviruses, 1998, 14, 1115-1128.	0.5	103
146	Comparison of the production of a human monoclonal antibody against HIV-1 by heterohybridoma cells and recombinant CHO cells: A flow cytometric study. Cytotechnology, 1996, 22, 129-138.	0.7	9
147	Biophysical Characterization of the Oligomeric States of Recombinant Immunoglobulins Type-M and Their C1q-Binding Kinetics by Biolayer Interferometry. Frontiers in Bioengineering and Biotechnology, O, 10, .	2.0	3